Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
37.23
+1.35 (3.76%)
At close: Jun 20, 2025, 4:00 PM
38.00
+0.77 (2.07%)
After-hours: Jun 20, 2025, 7:41 PM EDT
AAPG Employees
Ascentage Pharma Group International had 567 employees as of December 31, 2024. The number of employees decreased by 16 or -2.74% compared to the previous year.
Employees
567
Change (1Y)
-16
Growth (1Y)
-2.74%
Revenue / Employee
$236,953
Profits / Employee
-$97,964
Market Cap
3.15B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AAPG News
- 5 days ago - EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - GlobeNewsWire
- 11 days ago - Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - GlobeNewsWire
- 18 days ago - Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - GlobeNewsWire
- 18 days ago - Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - GlobeNewsWire
- 4 weeks ago - Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - GlobeNewsWire
- 2 months ago - Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - GlobeNewsWire
- 3 months ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga